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Induction of Glutathione S-Transferase-p in Barrett’s
Metaplasia and Barrett’s Adenocarcinoma Cell Lines
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Department of Surgery, Section of Thoracic Surgery, University of Michigan Medical School, Ann Arbor, Michigan
Barrett’s metaplasia consists of columnar epithelium that replaces the normal esophageal mucosa in patients
with chronic gastroesophageal reflux. Because intestinal-type Barrett’s metaplasia is the major risk factor for
adenocarcinoma development, understanding the mechanisms that predispose the esophageal mucosa to
malignant degeneration is clinically important. Glutathione S-transferase (GST)-π belongs to a class of protec-
tive enzymes whose activity has been shown to be much lower in Barrett’s metaplasia than in the normal
esophagus, where this form of GST is predominant. In the studies described here, using immunocytochemical
analysis, we observed higher levels of cytoplasmic GST-π protein in normal esophageal mucosa than in Barrett’s
metaplasia. Using northern blot analysis, we also observed lower GST-p mRNA levels in Barrett’s metaplasia
than in normal esophagus or adenocarcinomas from the same patients. Using as model systems three Barrett’s
adenocarcinoma cell lines and short-term organ culture of freshly resected normal esophagus and Barrett’s
metaplasia, dose-dependent induction of GST-p mRNA was observed by using butylated hydroxyanisole and
dexamethasone. GST-p mRNA in Barrett’s metaplasia was induced up to 2.5-fold with 60 µM butylated hy-
droxyanisole and nearly fivefold with 320 nM dexamethasone after 24 h. These studies demonstrate the ability
to induce protective GST-π in Barrett’s metaplasia and may suggest a mechanism for future chemoprevention
studies in patients with this type of epithelium, which is at high risk for malignant degeneration. Mol. Carcinog.
24:128–136, 1999. © 1999 Wiley-Liss, Inc.
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INTRODUCTION
Esophageal cancer is one of the 10 most common
cancers worldwide. Squamous cell carcinoma and ad-
enocarcinoma are the two main types. The incidence
of esophageal adenocarcinoma is increasing [1], and
the major risk factor for the development of esoph-
ageal adenocarcinoma is the presence of intestinal-
type Barrett’s metaplasia, a specialized condition in
which the distal squamous esophageal mucosa is re-
placed by columnar epithelium resembling that of the
normal intestine [2]. Development of Barrett’s meta-
plasia is a consequence of chronic gastroesophageal
reflux disease [3]; approximately 12% of patients who
suffer from gastroesophageal reflux disease develop
Barrett’s metaplasia [4]. Patients with Barrett’s meta-
plasia have a 30- to 40-fold higher incidence of esoph-
ageal adenocarcinoma than the general population
[2,5], and they are often enrolled in surveillance pro-
grams to facilitate early cancer detection. The pres-
ence of Barrett’s metaplasia is considered precancerous,
and progression from low- to high-grade dysplasia and
finally to esophageal adenocarcinoma is often observed
[2,6]. Similar genetic alterations are detected in Barrett’s
metaplasia and associated adenocarcinomas [7–9], in-
dicating that this type of epithelium may be suscep-
tible to critical DNA damage that leads to cancer
development.
The mechanisms underlying the dramatic increase
in the incidence of Barrett’s adenocarcinoma are un-
known but may be related to specific properties of
premalignant Barrett’s metaplasia. The intestinal-
type Barrett’s epithelium expresses cytochrome P450
isoenzymes, which can metabolically activate chemi-
cal carcinogens [10] (Hughes et al., manuscript sub-
mitted for publication). The specific cells expressing
cytochrome P450 isoenzymes are present in the glan-
dular, proliferative regions of the epithelium. The
dual ability to metabolically activate carcinogens and
retain proliferative capabilities may lead to the ac-
cumulation of DNA alterations. Relative to the nor-
mal esophageal mucosa, Barrett’s epithelium also has
reduced levels of glutathione S-transferases (GSTs)
[11], which are enzymes that play an important role
in detoxifying reactive electrophilic compounds cre-
ated by carcinogen metabolism within the cell [12].
GSTs are phase II enzymes that detoxify activated
carcinogens by enzymatic conjugation to glu-
tathione, thus rendering reactive compounds inac-
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tive, targeting them for excretion out of the cell, and
reducing the potential for genetic damage [13].
There are four GST isoforms in humans (α, µ, θ
and π) based on nucleotide homology and biochemi-
cal and immunologic criteria [14]. GST activity is
higher in the normal esophagus than in the gastric
epithelium [15], with the predominant form being
the GST-π isoenzyme. GST-π enzyme activity and
content are significantly lower in Barrett’s metapla-
sia, stomach, and duodenum than in normal esoph-
ageal mucosa [11]. Examination of tumor incidence
in tissues at several sites of the gastrointestinal tract
and their respective GST activities indicated that
where GST activity is lowest, tumor incidence is
highest [11].
Elevating the relatively low levels of GST in
Barrett’s metaplasia, especially the levels of GST-π,
may be one way to help prevent further neoplastic
development in this tissue. GSTs within different tis-
sues have been induced in rodent models [16–22].
Two compounds that have shown reasonable ability
to induce GST in murine tissues are the food addi-
tive and antioxidant butylated hydroxyanisole (BHA)
and the corticosteroid dexamethasone (Dex)
[12,13,16,23]. The ability of either BHA or Dex to
induce GSTs in human Barrett’s metaplasia has not
been previously examined. The aim of this study was
to examine the localization of the GST-π protein in
Barrett’s metaplasia and to determine whether BHA
or Dex could induce GST-p mRNA in human Barrett’s
metaplasia, normal esophageal mucosa, and esoph-
ageal Barrett’s adenocarcinoma cell lines.
MATERIALS AND METHODS
Human Tissues
After informed consent was obtained, normal
esophagus and Barrett’s metaplasia tissue samples
were taken from patients undergoing esophagectomy
for cancer at the University of Michigan Medical
Center. Only patients who had not received prior
chemotherapy or radiotherapy were included. Freshly
resected tissue samples were transported to the labo-
ratory in Dulbecco’s modified Eagle’s medium (Life
Technologies, Gaithersburg, MD) on ice. A portion
of each normal esophagus and Barrett’s metaplasia
samples was used immediately for short-term organ
culture, an additional portion was snap frozen in liq-
uid nitrogen and stored at –70°C for later RNA isola-
tion, and the remaining portion was placed in 10%
buffered formalin for 24 h at 4°C before processing
for paraffin embedding.
Immunohistochemical Analysis
The cellular localization and staining pattern of
the GST-π protein were examined by immunocy-
tochemical analysis of 5-µm formalin-fixed, paraf-
fin-embedded sections of Barrett’s metaplasia and
normal esophageal tissue. A polyclonal rabbit anti–
human GST-π antibody (Novocastra Laboratories,
Newcastle upon Tyne, UK) was used at a 1:100 dilu-
tion in phosphate-buffered saline containing 1%
bovine serum albumin. For the control reactions,
horse serum blocking solution was used instead of
the GST-π antibody. The avidin-biotin-peroxidase
complex method of antibody detection with 3,3′-
diaminobenzidine as the chromogen was used ac-
cording to the manufacturer’s recommendations
(Vecta-Stain-Elite; Vector Laboratories, Burlingame,
CA). The slides were lightly counterstained with he-
matoxylin, and the cellular localization and stain-
ing pattern of the GST-π protein was assessed by two
independent observers.
Short-Term Organ Culture
Barrett’s metaplasia and normal esophageal tissues
were cultured according to methods used for the
short-term organ culture of human and rodent small
intestine [24,25]. Immediately upon resection, a por-
tion of Barrett’s metaplasia or normal esophageal
mucosa was cut into approximately five or six 1-mm3
pieces and placed mucosa-side up onto stainless steel
mesh within the inner wells of 60-mm polystyrene
organ culture dishes (Becton Dickinson and Co.,
Franklin Lakes, NJ). The tissues were partially sub-
merged in 2.3 mL of growth medium containing
BHA, Dex, or the appropriate amount of ethanol (ve-
hicle control). The medium consisted of eight parts
of CMRL 1066 (Life Technologies) and two parts of
Ham’s F-12 nutrient mixture (Sigma Chemical Co.,
St. Louis, MO) supplemented with 10% fetal bovine
serum (Atlanta Biologicals, Norcross, GA), 25 mM
glucose, 2 mM L-glutamine, 5 µM ferrous sulfate, 0.1
µM sodium selenite, 100 µM 5-aminovulinic acid, 3
µM zinc sulfate, 145 nM menadione sodium bisulfite,
100 U/mL penicillin G, and 100 µg/mL streptomy-
cin sulfate. Sterile 0.9% NaCl solution was added to
the outer wells of the culture dishes, which were then
placed in a sealable tissue-culture incubation cham-
ber (Billups-Rothenburg Inc., Del Mar, CA). The
dishes were gassed for 20 min with 50% O2, 45% N2,
and 5% CO2 at 1700 mL/min, providing a minimum
of 14 volume exchanges of gas. The chamber with
the dishes was then sealed, and the entire unit was
placed in an orbital shaking incubator at 37°C and
40 rpm to provide gentle mixing and washing of
medium over the mucosa. The tissues were main-
tained under these conditions for 24 h and were then
collected, snap-frozen, and stored at –70°C until pro-
cessed for RNA extraction.
Tissue Culture of Human Cell Lines
Human esophagus (Het-1A) and Barrett’s adeno-
carcinoma (Seg-1, Flo-1, and Bic-1) cell lines were
used. The Seg-1, Flo-1, and Bic-1 cell lines were de-
rived from human esophageal Barrett’s adenocarci-
nomas. Het-1A is a normal human esophageal
mucosa cell line immortalized by using simian virus
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40 and has been previously described [26]. The cells
were grown in 10-cm tissue culture dishes with
Dulbecco’s modified Eagle’s medium containing 10%
fetal bovine serum, 100 U/mL penicillin G, and 100
µg/mL streptomycin sulfate at 37°C in a 5% CO2/
95% air humidified atmosphere. For the induction
experiments, 60 µM BHA, 320 nM Dex, or the ap-
propriate amount of 100% ethanol (vehicle control)
was added to fresh medium, and the cultures were
incubated for 24 h under the conditions described
above. After gentle washing in phosphate-buffered
saline, the cells were collected by scraping with a
rubber policeman and pelleted at 1200 rpm for 2 min
in 1.5-mL centrifuge tubes. The medium was then
removed, the cells were snap-frozen in liquid nitro-
gen, and the cell pellets were stored at –70°C until
processed for RNA isolation.
Total RNA Isolation
Frozen cell pellets and tissue pieces were homog-
enized with 1 mL of TRIzol Reagent (Life Technolo-
gies) by using the procedure recommended by the
manufacturer. The RNA pellets were then dissolved
in 1 mM EDTA, pH 7.0, in diethyl pyrocarbonate–
treated water. The RNA concentrations were deter-
mined by spectrophotometry at 260 nm, and 10-µg
aliquots were used for northern blot analysis.
Northern Blot Analysis
Northern blot analysis was performed as previously
described [27]. Total cellular RNA (10 µg) was sepa-
rated in 1.2% gels containing 2.2 M formaldehyde
and then vacuum-transferred to nylon membranes
(Gene Screen Plus; New England Nuclear, Wilming-
ton, DE). The membranes were prehybridized in 5×
standard saline phosphate with EDTA, 5× Denhardt’s
solution, 50% formamide, 3% sodium dodecyl sul-
fate, 5% dextran sulfate, 5 µg/mL heat-denatured
salmon-sperm DNA, and 3 µg/mL yeast tRNA for 1 h
at 48°C. Probes were labeled with [32P]dCTP by the
random-primer labeling method (Prime-It II;
Stratagene, La Jolla, CA), and unincorporated
[32P]dCTP was removed by Sephadex G-50 size-ex-
clusion chromatography. The membranes were hy-
bridized with 1.5 × 106 cpm/mL heat-denatured
32P-labeled probe for 16 h in a 48°C shaking water
bath. Then, the membranes were washed according
to the manufacturer’s recommendations, and auto-
radiograms were prepared (Hyperfilm-MP; Amersham
Corp., Arlington Heights, IL). Loading and transfer
of RNA was normalized by using a probe for 28S rRNA
as previously described [28]. Autoradiographic sig-
nals were quantified by scanning laser densitometry
(Molecular Dynamics, Sunnyvale, CA).
cDNA Probe Synthesis
A GST-p probe was designed by using the nucle-
otide sequence of the human GST-p cDNA [15]. Oli-
gonucleotide primers were designed to amplify the
GST-p cDNA by reverse transcription (RT)–poly-
merase chain reaction (PCR) of total RNA from nor-
mal esophageal squamous epithelium. Total RNA (2
µg) was reverse transcribed into cDNA by using ran-
dom hexamer primers (125 pmol/reaction; Promega
Corp., Madison, WI) in a solution containing 50 mM
Tris HCl, pH 8.3; 50 mM KCl; 8 mM MgCl2; 10 mM
dithiothreitol; and 1 mM each dATP, dCTP, dGTP,
and dTTP in a total volume of 25 µL. The reaction
mixture was heated to 65°C for 5 min and cooled to
41°C before avian myeloblastosis virus reverse tran-
scriptase was added (7 U/reaction; Boehringer
Mannheim, Indianapolis, IN). The reaction was al-
lowed to proceed for 1 h at 41°C. PCR of GST-p was
accomplished by adding 16 µL of the above RT mix-
ture to a 100-mL reaction containing 10 mM Tris
HCL, pH 8.3, 50 mM KCL; 1.5 mM MgCl2; 2 mM
dithiothreitol; 0.5 mM dNTPs; 12.5 pmol of each GST
primer, and 0.5 mL of Taq polymerase (Promega
Corp.). The sequence of the sense primer was 5′ CTC
AAA GCC TCC TGC CTA TAC 3′; the sequence of
the antisense primer was 5′ GGT AGT TAC CGT TGC
CCT TTG 3′. Amplification was done with an initial
cycle of 94°C for 1 min and then 35 cycles of 94°C
for 1 min, 57°C for 2 min, and 72°C for 3 min. Am-
plification produced the expected 498-bp GST-p PCR
product identified by using ethidium bromide–
stained 2% agarose gels, and then the band was cut
out of the gel, purified, and labeled for use as a probe
for northern blot analysis. Confirmation of the GST-
p PCR product was performed by automated DNA
sequencing at the University of Michigan.
RESULTS
Localization of GST-π Protein
Immunohistochemical analyses were performed on
normal esophageal and Barrett’s metaplasia tissue
sections. The localization and staining pattern of
GST-π protein within the Barrett’s metaplasia mu-
cosa differed from that of the normal esophageal
mucosa. Eight of 11 of the normal esophageal tissue
specimens examined displayed predominantly cyto-
plasmic GST-π protein expression (Figure 1A and B
and Table 1). A gradient of cytoplasmic GST-π pro-
tein was observed within the stratified squamous
epithelium, with higher concentrations nearer the
luminal surface and lesser amounts nearer the pro-
liferative basal areas. A combination of nuclear and
cytoplasmic GST-π staining was present in only three
of 11 specimens. In these cases, nuclear staining ap-
peared in the cells closest to the basal zone of the
squamous epithelium. In contrast, 11 of 15 Barrett’s
metaplasia tissue specimens demonstrated staining
primarily in the basal glandular regions of the mu-
cosa (Figure 1C and Table 1). More than half (seven
of 11) of the basal stained specimens displayed strong
nuclear staining of the GST-π protein; the other cases
showed equal cytoplasmic and nuclear staining. The
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Figure 1. GST-π protein expression in normal esophageal
tissue, non-dysplastic Barrett’s metaplasia, and dysplastic
Barrett’s mucosa. (A) Area of normal esophageal tissue (E) ad-
jacent to intestinal-type Barrett’s metaplasia mucosa. The abun-
dance of cytoplasmic GST-π protein expression in normal
esophageal tissue is contrasted with the lower levels of nuclear
GST-π staining in the Barrett’s metaplasia mucosa (arrows). (B)
Higher magnification of esophageal epithelium showing pre-
dominately cytoplasmic GST-π protein expression that is great-
est nearer the luminal surface and less near the basal prolifera-
tive zone (arrows). (C) Predominant GST-π nuclear staining
detected in the nuclei of most basal glandular regions (arrows)
of non-dysplastic Barrett’s metaplasia. (D) Increased cytoplas-
mic GST-π staining in areas of dysplasia (arrows) within the
Barrett’s mucosa but not in the non-dysplastic areas. Original
magnifications: panel A, 100×; panels B–D, 200×.
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basal glandular regions of Barrett’s metaplasia are
areas of active cell proliferation [29]. In contrast to
the levels in the non-dysplastic Barrett’s metaplasia,
the levels of GST-π staining increased dramatically
in dysplastic Barrett’s mucosa (Figure 1D) and ap-
peared to be both cytoplasmic and nuclear. These
results indicate a different pattern of GST-π localiza-
tion and staining in normal esophageal tissue and
Barrett’s metaplasia tissues.
GST-p mRNA Expression in Normal Esophagus,
Barrett’s Metaplasia, and Adenocarcinoma Tissue
GST-p mRNA levels were examined in the normal
esophageal mucosa, Barrett’s metaplasia, and adeno-
carcinoma tissues of five patients by using northern
blot analysis (Figure 2A). A GST-p mRNA transcript
of 0.6 kb was detected in all samples; however, in
four of the five patients, lower levels of GST-p mRNA
were present in Barrett’s metaplasia specimens than
in the normal esophagus. A modest increase in GST-
p mRNA above, the levels seen in corresponding
Barrett’s metaplasia specimens was present in the
adenocarcinomas in four of five patients. The ratio
of GST-p mRNA to 28S rRNA for each sample is shown
in Figure 2B. The GST-p mRNA levels in the Barrett’s
metaplasia samples were approximately 24% less
than the levels in the normal esophagus from the
same patients. The exception was patient PA-560,
who expressed more GST-p mRNA in the Barrett’s
metaplasia tissue; however, this patient’s Barrett’s
mucosa contained areas of dysplastic mucosa, which
may explain the higher levels of GST-p mRNA.
Induction of GST-p mRNA in Barrett’s
Adenocarcinoma and Normal Esophageal Cell Lines
To determine whether lower levels of protective
GST-π may increase the risk for adenocarcinoma de-
velopment in patients with Barrett’s metaplasia, we
examined the inducibility of GST-p in Barrett’s meta-
plasia. Cell lines of Barrett’s metaplasia are not avail-
able, so GST-p mRNA inducibility was examined by
northern blot analysis using three Barrett’s adeno-
carcinoma cell lines (Seg-1, Bic-1, and Flo-1) and the
immortalized esophageal squamous epithelium cell
line Het-1A (Figure 3A). Two of the three Barrett’s
adenocarcinoma cell lines (Seg-1 and Flo-1) demon-
strated increases in GST-p mRNA when treated with
30 µM BHA for 24 h (Table 2). The third cell line,
Bic-1, showed only modest induction over the basal
levels in three of four experiments with this com-
pound. The Bic-1 cells also had the highest basal lev-
els of GST-p mRNA of the three cell lines. Seg-1 and
Flo-1 had lower basal levels of GST-p mRNA and
showed greater induction with BHA. These results
may suggest that when physiological levels of GST-p
mRNA are lower, induction will be greater. Consis-
tent with this, GST-p mRNA was induced in Het-1A
cells with 30 µM BHA at somewhat lower levels than
those observed with Seg-1 and Flo-1 cells, and Het-
1A cells express relatively higher levels of GST-p
mRNA. Induction with Dex was also examined in
Seg-1 and Het-1A cell lines. Both cell lines demon-
strated low-level induction of GST-p mRNA with Dex
(Table 3).
The effects of increasing incubation times and BHA
concentration on GST-p mRNA induction were in-
vestigated by using Seg-1 and the normal squamous
cell line Het-1A, both of which showed the highest
levels of induction by BHA in our previous experi-
ments (Figure 3B). At 24 h of incubation, Seg-1 dis-
played a maximum level of GST-p mRNA induction
at 60 mM BHA, whereas Het-1A achieved its maxi-
mum induction at 30 mM BHA. Interestingly, the
Seg-1 cell line maintained near-maximal induction
of GST-p mRNA, whereas in the Het-1A cell line, the
mRNA levels began to taper off after 48 h.
GST-p mRNA Induction in Normal Esophageal and
Barrett’s Metaplasia
Although induction of GST-p mRNA was observed
in the esophageal and Barrett’s adenocarcinoma cell
lines, the induction of this mRNA also was exam-
ined in freshly resected normal esophagus and
Barrett’s mucosa by using organ culture (Figure 4).
After treatment of normal esophageal tissue with 60
µM BHA for 24 h, an average induction of 72% above
control levels was observed in three separate trials
(Table 2). A 64% induction of GST-p mRNA was ob-
served with Barrett’s metaplasia tissue after treatment
with BHA (Table 2). An even greater level of GST-p
mRNA induction of 123% was seen in Barrett’s meta-
plasia specimens treated with Dex (Table 3). These
results clearly demonstrate the ability of both com-
pounds to induce GST-p mRNA in Barrett’s metaplas-
tic tissue. The localization of GST-π protein after
induction was examined in seven patients’ Barrett’s
metaplasia and normal esophagus samples that had
been organ-cultured in the presence of either 80 nM
or 320 nM Dex for 24 h. Although these analyses are
not quantitative, an increased but relatively similar
Table 1. Localization of GST-π in Esophageal Tissues
No. of specimens Location within tissue
Tissue examined Basal region Upper region Both regions
Normal esophagus 11 0 (0%) 9 (82%) 2 (18%)
Barrett’s metaplasia* 15 11 (73%) 0 (0%) 4 (27%)
*Includes only non-dysplastic Barrett’s metaplasia.
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distribution of the GST-π protein in uncultured and
control samples was observed in the Barrett’s mu-
cosa (data not shown). A predominance of nuclear
staining in the glandular regions was observed in the
Barrett’s mucosa, whereas normal esophagus showed
increased cytoplasmic staining in the cellular layers
above the basal zone of the squamous mucosa.
DISCUSSION
Barrett’s metaplasia is a major risk factor for
esophageal adenocarcinoma development. The
mechanisms underlying increased cancer devel-
opment in this tissue are not known. However,
lower levels of certain protective enzymes such
as GSTs may increase the potential for this mu-
cosa to accumulate genetic alterations. Of the
GSTs, GST-π is the most prevalent isoform in the
Figure 2. (A) Northern blot analysis demonstrating GST-p
mRNA (0.6 kb) in normal esophageal tissue (N), Barrett’s meta-
plasia (B), and adenocarcinoma tissue (T) from five patients.
The 28S rRNA signals (4.4 kb) are shown in the lower panels.
(B) The ratio of GST-p mRNA to 28S rRNA for the tissue samples
from these five patients.
esophagus, and studies by Peters et al. [11] dem-
onstrated that Barrett’s metaplasia has signifi-
cantly less GST-π enzyme activity and content
than normal esophageal tissue. GST-p mRNA con-
tent has also been previously reported to be pro-
portional to GST-π enzyme activity [30]. We
observed GST-p mRNA levels in Barrett’s metapla-
sia an average of 24% lower than those of the
normal esophageal specimens from the same pa-
tients, which confirms the results of Peters et al.
[11]. These results suggest that this difference is
controlled at the level of GST-p transcription or
mRNA abundance. The difference in GST-π expres-
sion in these tissues does not appear to be due
simply to the presence of squamous versus colum-
nar cells, because small-intestine cells have high
GST levels, whereas gastric cells have low levels,
134 COMPTON ET AL.
yet both are columnar [11]. We also observed a
difference in the localization of the GST-π pro-
tein between the normal esophagus and Barrett’s
metaplasia. The GST-π protein was primarily cyto-
plasmic in the stratified squamous esophageal epi-
thelium, whereas the GST-π protein was mostly
localized to the nuclei of the cells within the basal,
glandular regions of Barrett’s mucosa. The signifi-
cance of this difference is uncertain, but a relation-
ship between nuclear GST-π protein expression and
cell proliferation may be involved. However, the
GST-π protein is known to exist in both nuclear and
cytoplasmic forms [31]. Lower overall levels of
GST-π in the actively proliferating cells of the glan-
dular regions of Barrett’s mucosa may make these
cells prone to the accumulation of genetic dam-
age caused by activated carcinogens. We have
found that intestinal-type Barrett’s metaplasia
expresses a number of cytochrome P450s known
to activate chemical carcinogens, and the cells
expressing these enzymes are in the proliferating
cellular regions of the metaplastic epithelium
(Hughes et al., manuscript submitted for publica-
tion). Interestingly, an increase in GST-π protein
was observed in some dysplastic Barrett’s mucosa
Figure 3. Northern blot analyses demonstrating induction
of GST-p mRNA in three Barrett’s adenocarcinoma cell lines (Seg-
1, Bic-1, and Flo-1) and the immortalized esophageal cell line
Het-1A. (A) The cell lines were incubated for 24 h with (+) and
without (–) 30 µM BHA. (B) The cells were treated with increas-
ing concentrations of BHA for the incubation times shown. The
28S rRNA signals are shown in the lower panels.
Table 2. BHA Induction of GST-p mRNA in Esophageal Cell Lines and Barrett’s metaplasia*
% Induction
Cell line or tissue Exp. 1 Exp. 2 Exp. 3 Exp. 4 Average induction*
Het-1A 24% 23% 7% NA 18% (3/3)
Seg-1 80% 67% 34% NA 60% (3/3)
Bic-1 31% 0% 0% 0% 8% (1/4)
Flo-1 6% 36% 0% 50% 23% (3/4)
Esophageal mucosa 42% 13% 161% NA 72% (3/3)
Barrett’s metaplasia 47% 155% 52% 0% 64% (3/4)
*Exp., experiment; NA, not analyzed. The numbers in parenthesis are the number of experiments in which results for a particular cell line were
obtained/the number of experiments performed.
(Figure 1D), and an increase in GST-p mRNA was
detected in some adenocarcinomas (Figure 2). In-
creased GST is known to occur in some tumors
and preneoplastic lesions [12,15,17] and may be
associated with selective chemoresistance in some
cancers.
We observed induction of GST-p mRNA in both
the squamous esophageal and Barrett’s metapla-
sia tissues after treatment with BHA and Dex.
Treatment of Barrett’s tissue with 60 µM BHA in
four separate experiments produced increases in
GST-p mRNA as high as 2.55-fold, and even greater
increases in GST-p mRNA were observed with 320
nM Dex. In addition, two of three Barrett’s ad-
enocarcinoma cell lines displayed increases in
GST-p mRNA after treatment with BHA (Seg-1,
60%; Flo-1, 23%). Seg-1 also showed a modest in-
duction in GST-p mRNA with Dex. Because these
Barrett’s adenocarcinoma cell lines demonstrated
inducibilities nearly similar to those of resected
Barrett’s mucosa, they may be an adequate model
for the analysis of additional agents capable of
inducing these important protective proteins. At
present, there are no Barrett’s metaplasia cell lines.
We examined the induction of GST-p by BHA and
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Dex because of their known ability to increase GSTs
in rodent models [12,13,16,23], and we demon-
strated here that these compounds also can induce
GST-p mRNA in Barrett’s metaplasia tissue in short-
term organ culture. The inducibility of GST in
Barrett’s mucosa may be important for future
chemopreventative agents in humans. Examples in-
clude the natural anticarcinogens coumarin, fla-
vone, phenethylisothiocyanate and oltipraz [20–22]
as well as nonsteroidal anti-inflammatory drugs
(NSAIDs), such as aspirin and ibuprofen [19]. These
compounds were shown to increase total GST en-
zyme activity, to increase specific GSTs in the ro-
dent esophagus, or to have both effects. Recent
analyses indicated that the risk of human esoph-
ageal cancers, including adenocarcinomas, is re-
duced in users of NSAIDs [32]. Although the exact
mechanism by which NSAIDs reduce esophageal
cancer risk is unknown, one mechanism may be by
induction of protective GST enzymes, as has been
demonstrated in rodents.
In summary, GST-p mRNA levels were reduced in
Barrett’s metaplasia compared with the normal
esophageal mucosa, consistent with the lower GST-
π enzyme activity and content reported in Barrett’s
metaplasia [11]. A difference in GST-π protein local-
ization between Barrett’s metaplasia and normal
esophagus was also observed. Most importantly, we
have shown, using short-term organ culture, the abil-
ity of BHA and Dex to induce GST-π in Barrett’s meta-
plasia. Further studies are necessary to determine
whether increasing protective GST-π may help reduce
adenocarcinoma development in patients with
Barrett’s metaplasia.
Table 3. Dex Induction of GST-p mRNA in Esophageal Cell Lines and Barett’s Metaplasia*
Cell line or tissue Exp. 1 Exp. 2 Average induction
Het-1A 3% 0% 3% (1/2)
Seg-1 0% 15% 15% (1/2)
Barrett’s metaplasia 59% 186% 123% (2/2)
*Exp., experiment. The numbers in parentheses are the number of experiments in which results for a particular cell line were obtained/the
number of experiments performed.
Figure 4. Northern blot analysis of GST-p mRNA induction
by BHA and Dex in organ-cultured normal esophagus (NE-1)
and Barrett’s mucosa (BM-1 and BM-2). The 28S rRNA signals
are shown in the lower panel.
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